The histamine H3 receptor as a therapeutic drug target for CNS disorders

Drug Discovery Today

Volumn 14, Issue 9-10, 2009, Pages 509-515

  Gemkow, Mark J ^a   Davenport, Adam J ^b   Harich, Silke ^a   Ellenbroek, Bart A ^a   Cesura, Andrea ^a   Hallett, David ^b  

^a EVOTEC AG   (Germany)

^b EVOTEC UK LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 (4 CYANOPHENYL) 2 [2 (2 METHYL 1 IMIDAZOLIDINYL)ETHYL]BENZOFURAN; BF2.649; CIPRALISANT; CIPROXIFAN; GSK 189254; GSK 207040; GT 2331; HISTAMINE H3 RECEPTOR; HISTAMINE H3 RECEPTOR AGONIST; HISTAMINE H3 RECEPTOR ANTAGONIST; IMETIT; JNJ 17216498; JNJ 5207852; MK 0249; NEUROTRANSMITTER; PERCEPTIN; PF 03654746; PLACEBO; SCH 497079; THIOPERAMIDE; TIPROLISANT; UNCLASSIFIED DRUG; WO 2008002817; WO 2008002820;

ALZHEIMER DISEASE; ATTENTION DEFICIT DISORDER; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL STUDY; CLINICAL TRIAL; DEPRESSION; DRUG TARGETING; HUMAN; KNOWLEDGE; NARCOLEPSY; NONHUMAN; OBESITY; OUTPATIENT DEPARTMENT; PAIN; PARKINSON DISEASE; PRESYNAPTIC NERVE; PROTEIN SECRETION; REVIEW; SCHIZOPHRENIA;

ANIMALS; CENTRAL NERVOUS SYSTEM DISEASES; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; DRUG INVERSE AGONISM; FORECASTING; HISTAMINE AGONISTS; HISTAMINE ANTAGONISTS; HUMANS; MODELS, BIOLOGICAL; RECEPTORS, HISTAMINE H3;

EID: 67349158641     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2009.02.011     Document Type: Review

References (63)

1. Arrang J.M., et al. Auto-inhibition of brain histamine-release mediated by a novel class (H-3) of histamine-receptor. Nature 302 (1983) 832-837
2. Morisset S., et al. High constitutive activity of native H-3 receptors regulates histamine neurons in brain. Nature 408 (2000) 860-864
3. Schlicker E., et al. Histamine H3 receptor-mediated inhibition of serotonin release in the rat brain cortex. Naunyn Schmiedebergs Arch. Pharmacol. 337 (1988) 588-590
4. Schlicker E., et al. Inhibition of noradrenaline release in the rat brain cortex via presynaptic H3 receptors. Naunyn Schmiedebergs Arch. Pharmacol. 340 (1989) 633-638
5. Schlicker E., et al. Histamine inhibits dopamine release in the mouse striatum via presynaptic H3 receptors. J. Neural Transm. Gen. Sect. 93 (1993) 1-10
6. 3H]-acetylcholine from slices of rat entorhinal cortex: evidence of the possible existence for H3 receptor subtypes. Br. J. Pharmacol. 107 (1992) 919-923
7. Drutel G., et al. Identification of rat H-3 receptor isoforms with different brain expression and signaling properties. Mol. Pharmacol. 59 (2001) 1-8
8. Martinezmir M.I., et al. Histamine receptor-H1, receptor-H2 and receptor-H3 visualized in the brain of human and nonhuman-primates. Brain Res. 526 (1990) 322-327
9. Cannon K.E., et al. Immunohistochemical localization of histamine H-3 receptors in rodent skin, dorsal root ganglia, superior cervical ganglia, and spinal cord: potential antinociceptive targets. Pain 129 (2007) 76-92
10. Bongers G., et al. Molecular aspects of the histamine H-3 receptor. Biochem. Pharmacol. 73 (2007) 1195-1204
11. Passani M.B., et al. The histamine H3 receptor as a novel therapeutic target for cognitive and sleep disorders. Trends Pharmacol. Sci. 25 (2004) 618-625
12. Wijtmans M., et al. Histamine H-3 receptor ligands break ground in a remarkable plethora of therapeutic areas. Expert Opin. Invest. Drugs 16 (2007) 967-985
13. Crawley J.N. Learning and memory. What' Wrong with My Mouse? Behavioral Phenotyping of Transgenic and Knockout Mice. 2nd edn (2007), Wiley 110-163
14. Toyota H., et al. Behavioral characterization of mice lacking histamine H-3 receptors. Mol. Pharmacol. 62 (2002) 389-397
15. Esbenshade T.A., et al. The histamine H-3 receptor: an attractive target for the treatment of cognitive disorders. Br. J. Pharmacol. 154 (2008) 1166-1181
16. Southam E., et al. Preclinical investigations into the antipsychotic potential of the novel H3 receptor antagonist GSK207040. Psychopharmacology 201 (2009) 483-494
17. Ellenbroek B.A., et al. Prepulse inhibition and latent inhibition: the role of dopamine in the medial prefrontal cortex. Neuroscience 75 (1996) 535-542
18. Fox G.B., et al. Pharmacological properties of ABT-239[4-(2-{2-[(2R)-2-methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H-3 receptor antagonist. J. Pharmacol. Exp. Ther. 313 (2005) 176-190
19. Brown R.E., et al. The physiology of brain histamine. Prog. Neurobiol. 63 (2001) 637-672
20. Ligneau X., et al. Neurochemical and behavioral effects of ciproxifan, a potent histamine H-3-receptor antagonist. J. Pharmacol. Exp. Ther. 287 (1998) 658-666
21. Le S.Y., et al. Correlation between ex vivo receptor occupancy and wake-promoting activity of selective H-3 receptor antagonists. J. Pharmacol. Exp. Ther. 325 (2008) 902-909
22. Parmentier R., et al. The brain H-3-receptor as a novel therapeutic target for vigilance and sleep-wake disorders. Biochem. Pharmacol. 73 (2007) 1157-1171
23. Leurs R., et al. The histamine H-3 receptor: from gene cloning to H-3 receptor drugs. Nat. Rev. Drug Discov. 4 (2005) 107-120
24. Lin J.S., et al. An inverse agonist of the histamine H-3 receptor improves wakefulness in narcolepsy: studies in orexin(-/-) mice and patients. Neurobiol. Dis. 30 (2008) 74-83
25. Farzin D., and Nosrati F. Modification of formalin-induced nociception by different histamine receptor agonists and antagonists. Eur. Neuropsychopharmacol. 17 (2007) 122-128
26. Huang L., et al. Histaminergic involvement in neuropathic pain produced by partial ligation of the sciatic nerve in rats. Reg. Anesth. Pain Med. 32 (2007) 124-129
27. Cannon K.E., and Hough L.B. Inhibition of chemical and low-intensity mechanical nociception by activation of histamine H-3 receptors. J. Pain 6 (2005) 193-200
28. Medhurst A.D., et al. Structurally novel histamine H-3 receptor antagonists GSK207040 and GSK334429 improve scopolamine-induced memory impairment and capsaicin-induced secondary allodynia in rats. Biochem. Pharmacol. 73 (2007) 1182-1194
29. Schwartz T.L., et al. Psychiatric medication-induced obesity: a review. Obes. Rev. 5 (2004) 115-121
30. Richelson E. Tricyclic antidepressants block histamine H1 receptors of mouse neuroblastoma cells. Nature 274 (1978) 176-177
31. Kim S.F., et al. Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 3456-3459
32. Itoh Y., et al. Feeding-induced increase in the extracellular concentration of histamine in rat hypothalamus as measured by in vivo microdialysis. Neurosci. Lett. 125 (1991) 235-237
33. Ookuma K., et al. Neuronal histamine in the hypothalamus suppresses food intake in rats. Brain Res. 628 (1993) 235-242
34. Morimoto T., et al. Brain histamine and feeding behaviour. Behav. Brain Res. 124 (2001) 145-150
35. Hancock A.A., and Brune M.E. Assessment of pharmacology and potential anti-obesity properties of H3 receptor antagonists/inverse agonists. Expert Opin. Invest. Drugs 14 (2005) 223-241
36. Yoshimoto R., et al. Therapeutic potential of histamine H3 receptor agonist for the treatment of obesity and diabetes mellitus. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 13866-13871
37. Medhurst A.D., et al. GSK189254, a novel H-3 receptor antagonist that binds to histamine H-3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models. J. Pharmacol. Exp. Ther. 321 (2007) 1032-1045
38. Ali S.M., et al. Design, synthesis, and structure-activity relationships of acetylene-based histamine H-3 receptor antagonists. J. Med. Chem. 42 (1999) 903-909
39. Celanire S., et al. Histamine H-3 receptor antagonists reach out for the clinic. Drug Discov. Today 10 (2005) 1613-1627
40. i and dangers associated with high clearance drugs in general. J. Pharm. Pharm. Sci. 2 (1999) 47-52
41. Lin J.H., and Lu A.Y.H. Inhibition and induction of cytochrome P450 and the clinical implications. Clin. Pharmacokinet. 35 (1998) 361-390
42. Cowart M., et al. Medicinal chemistry and biological properties of non-imidazole histamine H-3 antagonists. Mini Rev. Med. Chem. 4 (2004) 979-992
43. Sun M.H., et al. Synthesis and SAR of 5-amino- and 5-(aminomethyl)benzofuran histamine H-3 receptor antagonists with improved potency. J. Med. Chem. 48 (2005) 6482-6490
44. Nagase T., et al. Synthesis, structure-activity relationships, and biological profiles of a quinazolinone class of histamine H-3 receptor inverse agonists. J. Med. Chem. 51 (2008) 4780-4789
45. Lau J.F., et al. Ureas with histamine H-3-antagonist receptor activity - a new scaffold discovered by lead-hopping from cinnamic acid amides. Bioorg. Med. Chem. Lett. 16 (2006) 5303-5308
46. Zhao C., et al. The alkaloid conessine and analogues as potent histamine H-3 receptor antagonists. J. Med. Chem. 51 (2008) 5423-5430
47. Hancock A.A. The challenge of drug discovery of a GPCR target: analysis of preclinical pharmacology of histamine H-3 antagonists/inverse agonists. Biochem. Pharmacol. 71 (2006) 1103-1113
48. Altenbach R.J., et al. Synthesis, potency, and in vivo profiles of quinoline containing histamine H-3 receptor inverse agonists. J. Med. Chem. 50 (2007) 5439-5448
49. Axe F.U., et al. Three-dimensional models of histamine H-3 receptor antagonist complexes and their pharmacophore. J. Mol. Graph. Model. 24 (2006) 456-464
50. Esbenshade T.A., et al. Pharmacological and behavioral properties of A-349821, a selective and potent human histamine H-3 receptor antagonist. Biochem. Pharmacol. 68 (2004) 933-945
51. Fox G.B., et al. Differential in vivo effects of H-3 receptor ligands in a new mouse dipsogenia model. Pharmacol. Biochem. Behav. 72 (2002) 741-750
52. Esbenshade T.A., et al. Histamine H-3 receptor antagonists: preclinical promise for treating obesity and cognitive disorders. Mol. Interv. 6 (2006) 77-88
53. Fox G.B., et al. Two novel and selective nonimidazole H-3 receptor antagonists A-304121 and A-317920: II. In vivo behavioral and neurophysiological characterization. J. Pharmacol. Exp. Ther. 305 (2003) 3897-3908
54. Barbier A.J., et al. Acute wake-promoting actions of JNJ-5207852, a novel, diamine-based H-3 antagonist. Br. J. Pharmacol. 143 (2004) 649-661
55. Bonaventure P., et al. Histamine H-3 receptor antagonists: from target identification to drug leads. Biochem. Pharmacol. 73 (2007) 1084-1096
56. Santora V.J., et al. Novel H-3 receptor antagonists with improved pharmacokinetic profiles. Bioorg. Med. Chem. Lett. 18 (2008) 4133-4136
57. Santora V.J., et al. A new family of H-3 receptor antagonists based on the natural product Conessine. Bioorg. Med. Chem. Lett. 18 (2008) 1490-1494
58. Apodaca R., et al. A new class of diamine-based human histamine H-3 receptor antagonists: 4-(aminoalkoxy)benzylamines. J. Med. Chem. 46 (2003) 3938-3944
59. Roche O., and Sarmiento R.M.R. A new class of histamine H-3 receptor antagonists derived from ligand based design. Bioorg. Med. Chem. Lett. 17 (2007) 3670-3675
60. Lazewska D., et al. Piperidine variations in search for non-imidazole histamine H3 receptor ligands. Bioorg. Med. Chem. 16 (2008) 8729-8736
61. + channel blockers. Bioorg. Med. Chem. 12 (2004) 2307-2315
62. Ligneau X., et al. BF2.649 [1-{3-[3-(4-chlorophenyl)propoxy]propyl}piperidine, hydrochloride], a nonimidazole inverse agonist/antagonist at the human histamine H-3 receptor: preclinical pharmacology. J. Pharmacol. Exp. Ther. 320 (2007) 365-375
63. Barbier A.J., et al. Pharmacological characterization of JNJ-28583867, a histamine H3 receptor antagonist and serotonin reuptake inhibitor. Eur. J. Pharmacol. 576 (2007) 43-54